{"title":"在前列腺特异性抗原水平≥20 ng/mL的患者中,多变量无活检形态图预测具有临床意义的前列腺癌的发展和验证。","authors":"Mingzhe Chen, Shanqi Guo, Junxin Wang, Nan Wang, Simeng Wen, Hongtuan Zhang, Yong Wang, Ranlu Liu, Yong Xu, Xingkang Jiang","doi":"10.21037/tau-24-533","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL.</p><p><strong>Methods: </strong>The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibration plot, decision curve analysis, and the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Of 684 patients, 478 and 206 were randomly assigned to the diagnostic and validation cohorts, respectively. Multivariable predictors of csPCa included age, PSA density, PI-RADS, location of suspicious lesion, %PSA variation ratio, and acute urinary retention. The foundational nomogram achieved AUCs of 0.930 and 0.911 for the training and validation sets, respectively. By integrating both PHI and PSMA maximum standardized uptake value (SUVmax), the diagnostic accuracy of the advanced nomogram improved significantly, with AUCs of 0.951 and 0.935 for the training and validation sets, respectively. Limitations included the lack of external validation and potential selection bias.</p><p><strong>Conclusions: </strong>The biopsy-free nomogram presents a promising approach for accurate diagnosis of csPCa in patients with PSA levels ≥20 ng/mL. This non-invasive method can reduce unnecessary biopsies and enhance patient care by identifying those necessitating further evaluation and treatment.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 3","pages":"507-518"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986468/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.\",\"authors\":\"Mingzhe Chen, Shanqi Guo, Junxin Wang, Nan Wang, Simeng Wen, Hongtuan Zhang, Yong Wang, Ranlu Liu, Yong Xu, Xingkang Jiang\",\"doi\":\"10.21037/tau-24-533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL.</p><p><strong>Methods: </strong>The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibration plot, decision curve analysis, and the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Of 684 patients, 478 and 206 were randomly assigned to the diagnostic and validation cohorts, respectively. Multivariable predictors of csPCa included age, PSA density, PI-RADS, location of suspicious lesion, %PSA variation ratio, and acute urinary retention. The foundational nomogram achieved AUCs of 0.930 and 0.911 for the training and validation sets, respectively. By integrating both PHI and PSMA maximum standardized uptake value (SUVmax), the diagnostic accuracy of the advanced nomogram improved significantly, with AUCs of 0.951 and 0.935 for the training and validation sets, respectively. Limitations included the lack of external validation and potential selection bias.</p><p><strong>Conclusions: </strong>The biopsy-free nomogram presents a promising approach for accurate diagnosis of csPCa in patients with PSA levels ≥20 ng/mL. This non-invasive method can reduce unnecessary biopsies and enhance patient care by identifying those necessitating further evaluation and treatment.</p>\",\"PeriodicalId\":23270,\"journal\":{\"name\":\"Translational andrology and urology\",\"volume\":\"14 3\",\"pages\":\"507-518\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational andrology and urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tau-24-533\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational andrology and urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tau-24-533","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ANDROLOGY","Score":null,"Total":0}
Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.
Background: Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL.
Methods: The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibration plot, decision curve analysis, and the area under the receiver operating characteristic curve (AUC).
Results: Of 684 patients, 478 and 206 were randomly assigned to the diagnostic and validation cohorts, respectively. Multivariable predictors of csPCa included age, PSA density, PI-RADS, location of suspicious lesion, %PSA variation ratio, and acute urinary retention. The foundational nomogram achieved AUCs of 0.930 and 0.911 for the training and validation sets, respectively. By integrating both PHI and PSMA maximum standardized uptake value (SUVmax), the diagnostic accuracy of the advanced nomogram improved significantly, with AUCs of 0.951 and 0.935 for the training and validation sets, respectively. Limitations included the lack of external validation and potential selection bias.
Conclusions: The biopsy-free nomogram presents a promising approach for accurate diagnosis of csPCa in patients with PSA levels ≥20 ng/mL. This non-invasive method can reduce unnecessary biopsies and enhance patient care by identifying those necessitating further evaluation and treatment.
期刊介绍:
ranslational Andrology and Urology (Print ISSN 2223-4683; Online ISSN 2223-4691; Transl Androl Urol; TAU) is an open access, peer-reviewed, bi-monthly journal (quarterly published from Mar.2012 - Dec. 2014). The main focus of the journal is to describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research and clinical investigations of Andrology and Urology. Specific areas of interest include, but not limited to, molecular study, pathology, biology and technical advances related to andrology and urology. Topics cover range from evaluation, prevention, diagnosis, therapy, prognosis, rehabilitation and future challenges to urology and andrology. Contributions pertinent to urology and andrology are also included from related fields such as public health, basic sciences, education, sociology, and nursing.